Cell and Gene Outsourcing

  1. How IntegriCell™ Services In Belgium Ensure Cell Viability, Supply Chain Integrity 4/28/2025

    he effectiveness of cell-based therapies hinges on preserving cell viability, stability, and consistency. However, inconsistencies in cryopreservation methods have undermined therapeutic success.

  2. Transforming Patient Access To CGT 4/28/2025

    Chief Commercial Officer Aruna Mor recently delivered a powerful keynote at the Advanced Therapies Congress in London, highlighting the challenges of patient access to advanced therapies.

  3. Enabling The Outcome Through Enhancing Patient Accessibility 4/28/2025

    To ensure that the transformative potential of cell and gene therapy reaches every patient in need, we must prioritize equitable access and overcome the remaining barriers to widespread delivery.

  4. How BioServices Centers In France Enable Efficiency And Scalability 4/28/2025

    To support the growing demands of the ATMP industry, it's essential to leverage integrated biostorage, sample management, and regulatory solutions, and we are committed to enhancing these capabilities.

  5. Navigating CGT Biotech's Financial Headwinds And The Path Forward 4/24/2025

    Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.

  6. Selection And Evaluation Of Hybridization Capture Probes For LC/MS Analysis Of Oligonucleotides 4/23/2025

    To overcome challenges in oligonucleotide LC/MS bioanalysis, consider optimizing probe design by evaluating alternative chemistries like PNA for improved recovery and chromatographic performance.

  7. Advancing Cytokine, Immune Cell Characterization For Precision Bioanalysis 4/23/2025

    Unlock deeper insights into immune regulation and accelerate therapeutic discovery by adopting our next-generation inflammatory response assay.

  8. Expression Analysis Of CTLA-4, PD-1, And PD-L1 4/23/2025

    Advance personalized immunotherapy in NSCLC by leveraging qPCR-based analysis of CTLA-4, PD-1, and PD-L1 expression to identify predictive biomarkers and guide more effective treatment strategies.

  9. Optimizing qPCR For Broad-Range Transcript Detection In Anti-PD-1 Therapy 4/23/2025

    Optimize qPCR protocols for greater sensitivity and reproducibility to accurately measure immune-related gene expression and better identify patients who will benefit from anti-PD-1 immunotherapy.

  10. Quantifying, Mapping ATP Distribution Within Tissues To Inform Therapeutic Strategies 4/23/2025

    Leverage quantitative mass spectrometry imaging of ATP distribution to enhance tumor model selection and optimize targeted therapy development through precise mapping of metabolic activity.